Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 43.58 (-0.46), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), SLXP: 103.36 (-2.79)
Ironwood Pharmaceuticals doses diabetic gastroparesis patient under Phase IIa clinical study of IW-9179
M2 - Wed Dec 10, 6:32AM CST
Medicine company Ironwood Pharmaceuticals (NasdaqGS:IRWD) reported on Tuesday the start of a Phase IIa clinical study of IW-9179 in diabetic gastroparesis patients.
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis
Business Wire - Tue Dec 09, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in a Phase IIa clinical study evaluating whether its investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide symptomatic relief to patients with diabetic gastroparesis. Data are expected in the first half of 2016.
IRWD: 15.00 (+0.09)
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vhjzbs/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Functional (Non Ulcer) Dyspepsia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eisai Co., Ltd. - Zeria Pharmaceutical Co Ltd - Almirall, S.A. - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/vh...tional_non
IRWD: 15.00 (+0.09)
Synergy Pharmaceuticals Drug Fares Well in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 3:34PM CST
Synergy Pharmaceuticals (SGYP) announced positive top-line results from a phase II study on SP-333
SGYP: 2.93 (-0.05), ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), IRWD: 15.00 (+0.09)
Ironwood earns $15M milestone from Astellas
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 8:31AM CST
IRWD: 15.00 (+0.09)
Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
Business Wire - Thu Nov 20, 8:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that it has earned a $15 million development milestone payment from Astellas Pharma Inc., its partner for linaclotide in Japan. This milestone was triggered by Astellas's enrollment of the first patient in a randomized, double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with irritable bowel syndrome with constipation (IBS-C) in Japan. Astellas expects to complete the Phase III trial in 2016.
IRWD: 15.00 (+0.09)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.16 (+0.41), AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), IRWD: 15.00 (+0.09), CBST: 96.31 (+0.04), PFE: 30.95 (-0.70)
New finance chief at bluebird bio
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:56AM CST
BLUE: 91.28 (+5.16), IRWD: 15.00 (+0.09)
James M. DeTore joins bluebird bio as Chief Financial Officer
Business Wire - Mon Nov 10, 6:00AM CST
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that James M. DeTore is joining the company as its Chief Financial Officer and Treasurer and member of the company's leadership team.
BLUE: 91.28 (+5.16), IRWD: 15.00 (+0.09)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 2.93 (-0.05), FURX: 104.77 (-1.41), SYN: 1.47 (-0.04), IRWD: 15.00 (+0.09), LXRX: 0.85 (-0.05), AZN: 71.80 (-1.80), TEVA: 55.92 (-0.92)
Ironwood Pharmaceuticals (IRWD) Stock Downgraded Today at Cantor Fitzgerald
at The Street - Thu Nov 06, 12:28PM CST
Cantor Fitzgerald downgraded Ironwood Pharmaceuticals (IRWD) to 'sell' from 'hold' earlier on Thursday.
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 259.00 (-4.00), VRX: 138.71 (-0.18), IRWD: 15.00 (+0.09), AUXL: 33.11 (-0.72)
Ironwood Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
Business Wire - Wed Nov 05, 3:01PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 3:00 p.m. Mountain Time / 5:00 p.m. Eastern Time at the Arizona Biltmore in Phoenix.
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 6:30PM CST
IRWD: 15.00 (+0.09)
Ironwood beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:42PM CST
CAMBRIDGE, Mass. (AP) _ Ironwood Pharmaceuticals Inc. (IRWD) on Tuesday reported a loss of $42 million in its third quarter.
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals (IRWD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:25PM CST
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:13PM CST
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
Business Wire - Tue Nov 04, 3:06PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC). Linaclotide is currently approved by the U.S. Food and Drug Administration as a 145 mcg capsule to be taken once per day for the treatment of adults with CIC and as a 290 mcg capsule to be taken once per day for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
IRWD: 15.00 (+0.09)
Ironwood Pharmaceuticals Provides Third Quarter 2014 Investor Update
Business Wire - Tue Nov 04, 3:03PM CST
--- Four mid- to late-stage linaclotide clinical trials expected by year end 2014 -
IRWD: 15.00 (+0.09)